Clinical Trial Update: A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ENV-101 for idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease is listed as active but not re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Progressive Fibrosing Interstitial Lung Disease

Drugs mentioned

• ENV-101

Snippet

Sponsor: Endeavor Biomedicines, Inc. | Conditions: Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING